Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?

PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

(2021) Albert Gris-Oliver et al.   BRITISH JOURNAL OF CANCER

DrugComb update: a more comprehensive drug sensitivity data repository and analysis portal

(2021) Shuyu Zheng et al.   NUCLEIC ACIDS RESEARCH

The 2020 WHO Classification

(2020) Michael E. Kallen et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma

(2020) Monique Bernard et al.   Cancers

Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo

(2019) Kenta Watanabe et al.   Oncotarget

Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development

(2019) Daniel Y. Lee et al.   Cancer Medicine

Pleomorphic liposarcoma: Updates and current differential diagnosis

(2019) William J. Anderson et al.   SEMINARS IN DIAGNOSTIC PATHOLOGY

Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review

(2019) Khin Thway   SEMINARS IN DIAGNOSTIC PATHOLOGY

Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells

(2019) Christiane Margue et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer

(2019) Alina Malyutina et al.   PLoS Computational Biology

The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines

(2019) WATARU GOTO et al.   ANTICANCER RESEARCH

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells

(2019) Naotaka Hayasaka et al.   Scientific Reports

3D culture modelling: An emerging approach for Translational Cancer Research in Sarcomas

(2019) Victoria Heredia-Soto et al.   CURRENT MEDICINAL CHEMISTRY

Sarcoma Spheroids and Organoids—Promising Tools in the Era of Personalized Medicine

(2018) Gianluca Colella et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Soft Tissue and Uterine Leiomyosarcoma

(2018) Suzanne George et al.   JOURNAL OF CLINICAL ONCOLOGY

Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line

(2018) Kenichiro Yahiro et al.   Analytical Cellular Pathology

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2018) P G Casali et al.   ANNALS OF ONCOLOGY

The Influence of Metabolism on Drug Response in Cancer

(2018) Esther A. Zaal et al.   Frontiers in Oncology

Antitumor Effects of Eribulin Mesylate in Gemcitabine-resistant Pancreatic Cancer Cell Lines

(2016) YUKA TAKEZAKI et al.   ANTICANCER RESEARCH

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

(2016) Patrick Schöffski et al.   LANCET

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma

(2016) Alessandro De Vita et al.   MOLECULES

Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma

(2016) Valerie B. Sampson et al.   Oncotarget

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib

(2016) Mark A. Dickson et al.   JAMA Oncology

Eribulin in Cancer Treatment

(2015) Umang Swami et al.   Marine Drugs

What is synergy? The Saariselkä agreement revisited

(2015) Jing Tang et al.   Frontiers in Pharmacology

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

(2015) Bhagwan Yadav et al.   Computational and Structural Biotechnology Journal

3D tissue-engineered model of Ewing's sarcoma

(2014) Salah-Eddine Lamhamedi-Cherradi et al.   ADVANCED DRUG DELIVERY REVIEWS

Three-Dimensional Cell Culture Systems and Their Applications in Drug Discovery and Cell-Based Biosensors

(2014) Rasheena Edmondson et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

(2014) T Yoshida et al.   BRITISH JOURNAL OF CANCER

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

(2014) Yasuhiro Funahashi et al.   CANCER SCIENCE

Leiomyosarcoma

(2013) César Serrano et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance

(2013) David Monderer et al.   LABORATORY INVESTIGATION

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

(2013) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

(2012) Maria Vinci et al.   BMC BIOLOGY

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

(2011) Patrick Schöffski et al.   LANCET ONCOLOGY

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability

(2009) Jennifer A. Smith et al.   BIOCHEMISTRY